Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.64 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16546760 | 1.00 | DGAT1 (0.64) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL180807 | 1.00 | DGAT1 (0.64) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL180696 | 0.99 | DGAT1 (0.64) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL181111 | 0.92 | DGAT1 (0.67) | DGAT1SIRT7SOAT1VCP | |
| SCHEMBL180832 | 0.90 | DGAT1 (0.59) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL13664066 | 0.90 | DGAT1 (0.59) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL16549688 | 0.90 | DGAT1 (0.59) | DGAT1SIRT7SOAT1VCPFLT1 | |
| SCHEMBL14617024 | 0.89 | DGAT1 (0.63) | DGAT1SIRT7VCPFLT1FLT4 | |
| SCHEMBL16546763 | 0.89 | DGAT1 (0.63) | DGAT1SIRT7VCPFLT1FLT4 | |
| SCHEMBL180392 | 0.89 | DGAT1 (0.63) | DGAT1SIRT7VCPFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SIRT7 2961/4885SOAT1 4/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SIRT7 2961/4885SOAT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.